venetoclax – Medxy AI

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

By MedXY 09/09/2025

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against approved doublet therapies.

Clinical Updates Wellness & Lifestyle

ENHANCE-3 Trial: Evaluating Magrolimab Addition to Venetoclax and Azacitidine in Untreated AML Unfit for Intensive Chemotherapy

By MedXY 08/29/2025

The ENHANCE-3 phase 3 trial assessed whether adding magrolimab to venetoclax and azacitidine improves outcomes in untreated AML patients unfit for intensive chemotherapy, finding no survival benefit and a higher rate of fatal adverse events with magrolimab.

$Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial$

Clinical Updates Wellness & Lifestyle

Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial

By MedXY 08/07/2025

Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.

Clinical Updates Wellness & Lifestyle

Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

By MedXY 08/07/2025

A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.

Clinical Updates Wellness & Lifestyle

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

By MedXY 08/07/2025

A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.